Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
Taofeek K. Owonikoko(University of Maryland, Baltimore), David R. Spigel(Human Genome Sciences (United States))
Cited by 146